News:

Welcome to Qday.forum  :: Be kind, courteous and help other people.

Main Menu

AI and quantum for drug discovery: what is realistic in 2026 and what is still years away

Started by Glenn_44, Jun 01, 2026, 10:33 PM

Previous topic - Next topic

0 Members and 1 Guest are viewing this topic.

Topic: AI and quantum for drug discovery: what is realistic in 2026 and what is still years away   Views(Read 17 times)

Glenn_44

Multiple announcements this month connect AI and quantum technology to drug discovery and pharmaceutical research. Google REPLIQA targets protein folding dynamics and drug metabolism. Stellora AI's Quantum Flow covers protein interaction modelling and drug candidate screening. Novo Nordisk partnered with OpenAI for drug discovery AI across the entire business.

The honest 2026 picture: AI-assisted drug discovery is already producing results including the Vorinostat liver fibrosis repurposing finding from Google's Co-Scientist. Quantum-assisted drug discovery is producing research-stage results in specific narrow domains. The full quantum simulation of drug-protein interactions at clinical relevance is still a Level 2-3 quantum computing problem that current hardware cannot reach

DodgyCoder

The distinction between AI drug discovery and quantum drug discovery is important and often collapsed in coverage. Both are valuable and both are real but on very different timelines

RomoneyWalters

The Vorinostat result is the clearest near-term AI drug discovery outcome: an existing FDA-approved drug with a known safety profile identified for a new indication. The time-to-clinic is years not decades because the safety data already exists

MondayMoan31

Quantum simulation of molecular interactions requires the kind of fault-tolerant hardware that does not yet exist for problems at pharmaceutical scale. The hybrid quantum-classical approaches being deployed now are approximations, not exact solutions

Mike80

Google REPLIQA targeting utility-scale quantum advantage in life sciences by the early 2030s is the honest timeline. Near-term hybrid results will be incremental improvements on classical methods, not quantum advantage at scale
Lurker since the beginning

codeberg

The pharmaceutical industry is investing in quantum capability now for the 2030s payoff. The companies that understand the timeline and invest accordingly will be positioned when the hardware arrives